![Mitchel Sivilotti](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profil
Mitchel Sivilotti is associated with Omniabio, Inc. as the Chief Executive Officer.
Aktive Positionen von Mitchel Sivilotti
Unternehmen | Position | Beginn |
---|---|---|
Omniabio, Inc.
![]() Omniabio, Inc. BiotechnologyHealth Technology Omniabio, Inc. is a subsidiary of CCRM and is a contract development and manufacturing organization producing gene-modified cells and viral vectors, compliant with current good manufacturing practices standards. The private company's facility, located at McMaster Innovation Park in Hamilton, Canada, will be the first commercial-scale CDMO dedicated to cell and gene therapies and is expected to be the largest facility of its kind. The company is based in Hamilton, Canada and is supported by the government of Ontario via the Invest Ontario Fund. Omniabio will anchor a biomanufacturing center of excellence and will open in three phases between 2024 and 2026. The CEO of the Canadian company is Mitchel Sivilotti. | Vorstandsvorsitzender | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Omniabio, Inc.
![]() Omniabio, Inc. BiotechnologyHealth Technology Omniabio, Inc. is a subsidiary of CCRM and is a contract development and manufacturing organization producing gene-modified cells and viral vectors, compliant with current good manufacturing practices standards. The private company's facility, located at McMaster Innovation Park in Hamilton, Canada, will be the first commercial-scale CDMO dedicated to cell and gene therapies and is expected to be the largest facility of its kind. The company is based in Hamilton, Canada and is supported by the government of Ontario via the Invest Ontario Fund. Omniabio will anchor a biomanufacturing center of excellence and will open in three phases between 2024 and 2026. The CEO of the Canadian company is Mitchel Sivilotti. | Health Technology |